Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 928 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

NAŘÍZENÍ XXXXXX V XXXXXXXXX XXXXXXXXX (EU) 2020/1182

xx xxx 19. xxxxxx 2020,

xxxxxx se xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx x vědeckému xxxxxxx mění xxxx 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1272/2008 o xxxxxxxxxxx, označování x xxxxxx xxxxx x xxxxx

(Xxxx s xxxxxxxx xxx XXX)

XXXXXXXX KOMISE,

s xxxxxxx xx Smlouvu x fungování Evropské xxxx,

x xxxxxxx xx xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 x klasifikaci, xxxxxxxxxx x xxxxxx xxxxx x xxxxx, x změně x xxxxxxx xxxxxxx 67/548/XXX x 1999/45/ES a x xxxxx xxxxxxxx (XX) x. 1907/2006&xxxx;(1), x xxxxxxx xx xx. 37 xxxx. 5 uvedeného xxxxxxxx,

xxxxxxxx x těmto důvodům:

(1)

Tabulka 3 x části 3 xxxxxxx VI xxxxxxxx (ES) č. 1272/2008 xxxxxxxx seznam xxxxxxxxxxxxxxx klasifikací x xxxxxxxx nebezpečných xxxxx xx základě xxxxxxxx xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx X uvedeného xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx xxx xxxxxxxx látky („xxxxxxxx“) xxxx x xxxxxxx x článkem 37 xxxxxxxx (XX) č. 1272/2008 xxxxxxxxxx návrhy xx xxxxxxxx harmonizované xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx jiných xxxxx. Xx xxxxxxx xxxxxxxxxx&xxxx;(2) x xxxxx xxxxxxx, xxxxx xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („XXX“) xxxxxxxx, xxxxx x xxxxxxxxxx xxxxxxxxxxxx stran, je xxxxxx xxxxxx, aktualizovat xx zrušit xxxxxxxxxxxxx xxxxxxxxxxx x označení xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx výboru XXX xxxx:

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxx xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxx x xxxxxxx xxxxxxx (x xxxxxxx &xx; 3 μx,xxxxx > 5 μx x xxxxxx xxxxx ≥ 3:1),

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, trimethoxy(vinyl)silanu,

—

stanovisko xx xxx 8. xxxxxx 2018 ohledně xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 ohledně granulované xxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxx (N-hydroxy-N-nitrosocyklohexylaminato-O,O’)-mědi, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Cu-HDO],

—

stanovisko xx xxx 14. xxxx 2018 ohledně xxxxxxxxxx-xxxxxxxxx, [1] stannanu, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2],

—

xxxxxxxxxx ze dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (ISO), (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanolu,

—

stanovisko xx dne 8. xxxxxx 2018 ohledně xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxx (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2E)-3,7-dimethylokta-2,6-dien-1-olu,

—

stanovisko xx xxx 28. xxxxx 2019 xxxxxxx 2-(4-terc-butylbenzyl)propionaldehydu,

—

stanovisko xx dne 9. xxxxxx 2018 ohledně XXXX-xxxxxxxxxx (ISO), X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, S-ethyl 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, flupyradifuronu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx kyseliny,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx glyoxylové xxxxxxxx …%,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [xxxxxxxxxxx xxxxxxxx z xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx draselného, cyklohexyl(hydroxy)diazen-1-oxidu, xxxxxxxx soli, [X-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfátu, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx ze dne 9. xxxxxx 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (ISO), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx 3-chlor-4-(chlormethyl)-1-[3-trifluormethyl)fenyl]pyrrolidin-2-onu, xxxxxxxxxxxxxxx (ISO),

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně 4,5-dichlor-2-oktyl-2H-isothiazol-3-onu, [XXXXX],

—

xxxxxxxxxx ze dne 8. xxxxxx 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [XXXX],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, fluxapyroxadu,

—

stanovisko ze xxx 8. června 2018 xxxxxxx N-(hydroxymethyl)akrylamidu, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx xx xxx 15. xxxxx 2018 ohledně 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx iprovalikarbu (XXX), isopropyl [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (ISO), N-allyl-4,5-dimethyl-2(trimethylsilyl)thiofen-3-karboxamidu,

—

stanovisko xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx studena xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, extrahovaný xxxxxxxxxxxxxx xxxxxx xxxxxxxxx],

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx …%[C> 70 %],

—

xxxxxxxxxx z 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxxxx-xxxxxxx (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,

—

stanovisko ze 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, ethylenglykol-monobutyl-etheru,

—

stanovisko ze xxx 30. xxxxxxxxx 2018 xxxxxxx m-bis(2,3-epoxypropoxy)benzenu, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx ze xxx 14. září 2018 xxxxxxx tribenuron-methylu (ISO), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 ohledně xxxxxxxxxxxxx (XXX), xxxxxx (E)-2-{2-[6-(2-kyanofenoxy)pyrimidin-4-yloxy]fenyl}-3-methoxyakrylátu,

—

stanovisko xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx mesotrionu (ISO), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx okthilinonu (ISO), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [OIT],

—

stanovisko xx xxx 14. xxxx 2018 ohledně hymexazolu (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,

—

stanovisko xx xxx 9. xxxxxx 2018 ohledně pymetrozinu (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), xxxxxxx xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko ze xxx 14. září 2018 xxxxxxx-xxxxx, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx rozvětveného xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx hexyl 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x xxxxx xxxxx (xxxxx CAS 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (xxxxx x prášku; [průměr xxxxxx &xx; 1 xx];) x 082–014–00–7 (xxxxxxxx olovo; [průměr xxxxxx ≥ 1 xx];)), XXX xx xxxx xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxx použít xxxxxxx xxxxxxxxxxxxxxx klasifikaci xx xxxxxxxxx x xxxxxxxxx xxxxx. Xxxxx xxxxxxxx x xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxx struktuře xxxxx, xx xxxxxxxxxx xxxxxxx xxxxxx xxxxxx x xxxxxxxx x xxxxx environmentální klasifikaci x xxxxxxxxxx x xxxxxxxxxx xxxxx xxxxxx xxxx v xxxxxxxxxxxx xxxxxxxxx v příloze XX musí XXX xxxxxxx další xxxxxxxxx xxxx, xxx xx xxx xx xxxxxxxxx x xxxxxxxxx xxxxx xxxxx použita xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Xxxxx xxxx xxxx xxxxxxxxxx xxxx vědecké xxxxxxxx, x xxxxx xxxxxxx, xx xxxxxxxxxxxxxxx xxxxxxxxxxx xxx celistvou xxxxx, xxx ji xxxxxxxxxx xxxxxxxxxx výboru RAC, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx xxxxx xxxxx xxxxxx xxxxxxxx xx xxxxxxx XX xxxxxxxx (XX) x. 1272/2008, xxxxx RAC nebude xxx xxxxxxx předložit xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x látku 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), xxx třídu xxxxxxxxxxxxx „akutní xxxxxxxx (xxxxxxxxx)“ byly předloženy xxxx xxxxxxx xxxxxxxx, xx xxxxxxx vyplývá, xx xxxxxxxxxxx xxx xxxx třídu nebezpečnosti xxxxxxxxxxxx xx stanovisku xxxxxx XXX, jež xx zakládá xx xxxxxxxx údajích, xxxxxx xxx xxxxxx. Xxxx xxxxx xxxxxxxxxxxxx by xxxxx neměla xxx x xxxxxxx VI xxxxxxxx (XX) x. 1272/2008 xxxxxxx, xxxxx XXX xxxxxx xxx xxxxxxx xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; xxxxxxx xxxxxxx třídy xxxxxxxxxxxxx, x xxxxxxx pojednává xxxxxxxxxx xxxxxx XXX, xx zařazeny být xxxx.

(5)

Xxxxxxxx (XX) x. 1272/2008 by xxxxx xxxx být odpovídajícím xxxxxxxx změněno.

(6)

Dodržování xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxx xxx, s výhradou xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxx xx to, xxx přizpůsobili označování x xxxxxx xxxxx x xxxxx xxxxx xxxx revidovaným klasifikacím x xxxxxxx xxxxxxxxx xxxxxx. Tato xxxx xx rovněž xxxxxxxx x xxxx, aby xxxxxxxxxx měli xxxxxxxx xxxx přijmout xxxxxxxx xxxxx k xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx v důsledku xxxx xxxxxxxxxxx podle xxxxxx xxxxxxxx. Tyto xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx x xx. 22 odst. 1 písm. f) xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 1907/2006 (3) xxxx xxxxxxxxx xxxxxxxxx v xxxxxx 50 nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by xxxx xxxx být xxxxxxxx, xxx xxxxx nová xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, označování a xxxxxx xxxxxxxxxx dobrovolně xxxxx xxxx použitelnosti xxxxxx xxxxxxxx. Xx xx x xxxxxxx x přístupem xxxxx xx. 61 xxxx. 2 nařízení (XX) x. 1272/2008,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx 1

Změny xxxxxxxx (XX) x. 1272/2008

Xxxxxxx 3 x části 3 přílohy XX xxxxxxxx (ES) č. 1272/2008 xx xxxx x xxxxxxx x xxxxxxxx xxxxxx nařízení.

Článek 2

Vstup v xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx dvacátým dnem xx xxxxxxxxx x Xxxxxxx xxxxxxxx Evropské xxxx.

Xxxxxxx se xxx xxx 1. března 2022.

Xxxxxxxx od xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx látky x xxxxx xxxxxxxxxxxxx, xxxxxxxxxx x xxxxxx x xxxxxxx x xxxxxxxxx (XX) x. 1272/2008 xx znění xxxxxx xxxxxxxx xxxxx xxxxx dnem 1. xxxxxx 2022.

Toto nařízení xx xxxxxxx v xxxxx xxxxxxx a xxxxx xxxxxxxxxx ve xxxxx xxxxxxxxx xxxxxxx.

X Xxxxxxx xxx 19. května 2020.

Xx Xxxxxx

Xxxxxx XXX XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx xx xxxx xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1907/2006 xx xxx 18. xxxxxxxx 2006

o xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx chemických xxxxx, x zřízení Xxxxxxxx xxxxxxxx pro xxxxxxxx látky, x xxxxx směrnice 1999/45/XX x x xxxxxxx xxxxxxxx Rady (XXX) x. 793/93, nařízení Xxxxxx (XX) x. 1488/94, směrnice Rady 76/769/XXX x xxxxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX a 2000/21/XX (Xx. věst. X 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012 ze xxx 22. xxxxxx 2012

x dodávání xxxxxxxxxx xxxxxxxxx xx xxx x xxxxxx používání

(Úř. xxxx. X 167, 27.6.2012, x. 1).

PŘÍLOHA

V xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 xx xxxxxxx 3 x xxxxx 3 mění takto:

1)

Vkládají xx tyto položky:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx ES

Číslo XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx faktory x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx slov

Kódy standardních xxx o nebezpečnosti

Kódy xxxxx. xxxxxxxxxxxx xxx x nebezpečnosti

„007-030-00-3

kyselina xxxxxxx …% [C ≤ 70 %]

231-714-2

7697-37-2.

Ox. Xxx. 3

Xxxxx Xxx. 3

Skin Xxxx. 1 A

H272

H331

H314

GHS03

GHS06

GHS05

Dgr

H272

H331

H314

EUH071

Ox. Xxx. 3; H272: X ≥ 65 %

xxxxxxxxx: XXX = 2,65 mg/l (xxxx)

Xxxx Xxxx. 1 X; X314: X ≥ 20 %

Xxxx Xxxx. 1X; X314: 5 % ≤ X &xx; 20 %

B“

„014-048-00-5

vlákna x xxxxxxx xxxxxxx (x průměru < 3 μx, xxxxx &xx; 5 μx x x poměrem xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Xxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 3

XXXX XX 3

XXXX SE 1

Eye Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H225

H331

H301

H336

H370 (horní xxxxxxx cesty, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx xxxxxxx cesty, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: ATE = 5 xx/x (xxxx)

xxxxxx: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

xxxxxxxxxxx xxx;

[xxxxx xxxxxx: xx 0,9 xx x xx 6,0 mm; xxxxx částic: xx 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Acute Xxx. 4

XXXX XX 2

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

xxxxxxx, xxxxxxx-, bis(koko acyloxy) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1X

XXXX XX 1

X360X

X372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X372 (xxxxxxxx xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1B; X350: X ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (XXX);

(1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx

–

125225-28-7

115850-69-6

115937-89-8

Xxxx. 1X

Xxxxx Xxx. 4

XXXX XX 2

Aquatic Xxxxxxx 1

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

xxxxxx: ATE = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (ISO);

(2RS,3RS)-1-(4-chlorfenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol

–

76738-62-0

Repr. 2

Xxxxx Xxx. 4

Xxxxx Tox. 4

Xxx Irrit. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 mg/l (prach xxxx mlha)

orální: XXX = 490 xx/xx XX

X = 10

X = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxx

246-831-4

25319-90-8

Xxxxx Xxx. 4

XXXX XX. 2

Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1

X302

X373 (játra)

H400

H410

GHS07

GHS08

GHS09

Wng

H302

H373 (xxxxx)

X410

xxxxxx: ATE = 450 xx/xx XX

X = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„607-741-00-4

4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H302

H373 (svalovina)

H400

H410

GHS07

GHS08

GHS09

Wng

H302

H373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 mg/kg XX

X = 10

M = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx kyselina;

(2 S)-2-hydroxypropanová xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1C

Eye Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Liq. 3

Xxxx. 2

Xxxx. 1X

Xxxxx Xxx. 3

Acute Xxx. 4

Xxxx Xxxx. 1X

Xxx Xxx. 1

Skin Sens. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: ATE = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx xxxxxxxx …%

206-058-5

298-12-4

Xxx Dam. 1

Skin Xxxx. 1B

H318

H317

GHS05

GHS07

Dgr

H318

H317

B“

„607-746-00-1

natrium-N-(hydroxymethyl)glycinát;

[formaldehyd xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1B

Muta. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

XXXX SE 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: ATE = 3 mg/l (xxxxx xxxx xxxx)

xxxxxx: XXX = 1 100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, xxxxxxxx xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Xxxxx Xxx. 3

STOT RE 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Xxxxxxx Chronic 2

X228

X301

X373 (játra)

H315

H318

H411

GHS02

GHS06

GHS08

GHS05

GHS09

Dgr

H228

H301

H373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx TH“

„612-294-00-3

mecetroniumetilsulfát;

N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfát;

mecetronium-ethyl-sulfát;

[MES]

221-106-5

3006-10-8

Skin Corr. 1

Xxx Dam. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

X = 1 000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Xxxxxxx Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1

X = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (ISO);

1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluormethyl)-1H-pyrazol-1-yl]ethanon

–

1003318-67-9

Aquatic Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1B

Acute Xxx. 2

Xxxxx Tox. 3

XXXX XX 1

Xxx Xxx. 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: XXX = 0,14 mg/l (xxxxx xxxx mlha)

orální: XXX = 221 xx/xx TH

M = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1B

Acute Xxx. 4

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: ATE = 500 xx/xx XX

X = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]

264-843-8

64359-81-5

Acute Xxx. 2

Xxxxx Xxx. 4

Skin Xxxx. 1

Eye Xxx. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: ATE = 0,16 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Xxxxx. 2; X315: 0,025 % ≤ C &xx; 5 %

Xxx Xxxxx. 2; X319: 0,025 % ≤ X < 3 %

Xxxx Sens. 1 X; H317: X ≥ 0,0015 %

X = 100

X = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Tox. 4

Acute Xxx. 3

Xxxx Corr. 1X

Xxx Xxx. 1

Skin Xxxx. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX

xxxxxx: XXX = 175 xx/xx XX

Xxxx Sens. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

X = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1B

STOT XX 1

X350

X340

X372 (xxxxxxxxx xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (periferní xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 1

X = 1“

„616-232-00-6

xxxxxxxxxxxx (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

H351

GHS08

Wng

H351“

„616-233-00-1

silthiofam (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Aquatic Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx skořápek, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx]

283-644-7

84696-25-3

Xxxxxxx Xxxxxxx 3

H412

H412“

2)

položky xxxxxxxxxxxx xxxxxxxxx xxxxxx 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 a 617–006–00-X xx nahrazují xxxxxx xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x ATE

Poznámky

Kódy xxxx a xxxxxxxxx xxxxxxxxxxxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x signálních xxxx

Xxxx xxxxxxxxxxxx xxx x nebezpečnosti

Kódy xxxxx. xxxxxxxxxxxx xxx o xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X > 70 %]

231-714-2

7697-37-2

Xx. Liq. 2

Xxxxx Xxx. 1

Xxxx Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Xxx. 2; X272: X ≥ 99 %

Xx. Xxx. 3; H272: 70 % ≤ X < 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Aquatic Xxxxxxx 1

X361x ***

H410

GHS08

GHS09

Wng

H361f ***

X410

X = 10“

„015-134-00-5

pirimifos-methyl (ISO);

O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforothioát

249-528-5

29232-93-7

Acute Xxx. 4

STOT RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H302

H372 (nervový xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (nervový xxxxxx)

X410

xxxxxx: XXX = 1 414 xx/xx XX

X = 1&xxxx;000

X = 1 000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Gas 1

Press. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1B

Aquatic Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (xxxxx)

X“

„050-021-00-4

xxxxxxxxxxxxxxxxxxxxx

222-583-2

3542-36-7

Xxxx. 1X

Xxxxx Xxx. 2

XXXX RE 1

Xxxxxxx Chronic 3

H360D

H330

H372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

X412

Xxxx. 1X; X360 X: C ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (prach xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (imunitní systém)

H400

H410

GHS08

GHS09

Dgr

H360D

H372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx prášek; [xxxxxx xxxxxx &xx; 1 mm]

231-100-4

7439-92-1

Repr. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

H360FD

H362

H400

H410

GHS08

GHS09

Dgr

H360FD H362

H410

Repr. 1 X; X360X: X ≥ 0,03 %

X = 1

M = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Tox. 4*

Xxxxx Tox. 4

Skin Xxxxx. 2

Xxx Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Skin Xxxxx. 2

Xxx Irrit. 2

Xxxx Xxxx. 1

Aquatic Xxxxxxx 3

H350

H341

H311

H302

H315

H319

H317

H412

GHS08

GHS06

Dgr

H350

H341

H311

H302

H315

H319

H317

H412

dermální: ATE = 300 xx/xx XX xxxxxx: ATE = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (XXX);

xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx

401-190-1

101200-48-0

XXXX XX 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

ethofumesát (ISO);

(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Xxxxx Xxx. 3

Xxxxx Xxx. 2

XXXX RE 1

Aquatic Xxxxx 1

X331

X311

X300

X372

X400

XXX06

XXX08

XXX09

Xxx

X331

X311

X300

X372

X400

xxxxxxxx: XXX = 300 xx/xx XX xxxxxx: XXX = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (ISO);

2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyklohexandion

–

104206-82-8

Repr. 2

XXXX XX 2

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X373 (xxx, xxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

M = 10“

„613-112-00-5

xxxxxxxxxx (ISO);

2-oktyl-2H-isothiazol-3-on; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 3

Skin Xxxx. 1

Eye Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (xxxxx xxxx xxxx)

xxxxxxxx: XXX = 311 mg/kg XX xxxxxx: XXX = 125 xx/xx TH

Skin Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Tox. 4

Xxx Xxx. 1

Skin Xxxx. 1

Xxxxxxx Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 xx/xx XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Aquatic Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (ISO);

reakční xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát

428-790-6

72963-72-5

Carc. 2

Xxxxx Xxx. 4

Xxxxx Tox. 4

XXXX SE 2

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (prach xxxx xxxx)

xxxxxx: XXX = 550 xx/xx TH

M = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Xxx. 4

Acute Xxx. 3

STOT XX 3

XXXX XX 1

STOT XX 2

Skin Xxxxx. 2

Xxx Xxx. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx cesty)

H373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (xxxxxx oběh)

H315

H318

H317

dermální: XXX = 1 100 xx/xx XX xxxxxx: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Perox. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Aquatic Xxxxxxx 2

X242

X360X

X315

X319

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X242

X360X

X315

X319

X411“

3)

xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx 601-064-00-8 x 607-693-00-4 xx xxxxxxx.